Myocarditis following COVID-19 mRNA vaccination |
| |
Institution: | 1. Department of Internal Medicine B, Hillel Yaffe Medical Center, Hadera, Israel;2. Rappaport Faculty of Medicine, Israel Institute of Technology, Haifa, Israel;3. Department of Cardiology, Hillel Yaffe Medical Center, Hadera, Israel;4. Department of Imaging, Hillel Yaffe Medical Center, Hadera, Israel;5. Infectious Disease Unit, Hillel Yaffe Medical Center, Hadera, Israel;6. Department of Nephrology, Hillel Yaffe Medical Center, Hadera, Israel |
| |
Abstract: | BackgroundClinical trials of the BNT162b2 vaccine, revealed efficacy and safety. We report six cases of myocarditis, which occurred shortly after BNT162b2 vaccination.MethodsPatients were identified upon presentation to the emergency department with symptoms of chest pain/discomfort. In all study patients, we excluded past and current COVID-19. Routine clinical and laboratory investigations for common etiologies of myocarditis were performed. Laboratory tests also included troponin and C-reactive protein levels. The diagnosis of myocarditis was established after cardiac MRI.FindingsFive patients presented after the second and one after the first dose of the vaccine. All patients were males with a median age of 23 years. Myocarditis was diagnosed in all patients, there was no evidence of COVID-19 infection. Laboratory assays excluded concomitant infection; autoimmune disorder was considered unlikely. All patients responded to the BNT162b2 vaccine. The clinical course was mild in all six patients.InterpretationOur report of myocarditis after BNT162b2 vaccination may be possibly considered as an adverse reaction following immunization. We believe our information should be interpreted with caution and further surveillance is warranted. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|